Highlights
1 patentProfile claimed by owner
About
Nucleic Acid-based Vaccine Platform
ViVac is a revolutionary viral vaccine platform that immunizes against all viral proteins by safely and precisely mimicking actual viral infections. The platform is designed to provide more robustness and long-lasting immunity than mRNA/DNA and traditional vaccines while maintaining cost-effective production and enabling scale to meet new viral threats.
ViVac was founded by two of the world’s leading experts in synthetic biology and nano drug delivery.
Identity
| Name | ViVac |
|---|---|
| Slug | vivac |
| Type / kind | startup |
| Source _id | vKv2jmO8G0c8o7u5Xq0akQUPRTAhFJ8MagXPuKrTXq10fzSATGPXzg |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Tel Aviv-Yafo |
| HQ address | Me'ir Ya'ari St 24, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://content.celero.io/s/0d316a30/vivac-non-confidential-jan-23/ |
|---|---|
| Careers page | https://content.celero.io/careers |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
drug-deliveryvaccines-developmentvaccinespharmaceuticalsimmunology
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}